Reasons To Limit Inventor Testimony In Hatch-Waxman Cases

By Michael Hogan (February 14, 2019, 2:59 PM EST) -- Inventor testimony inevitably forms a part of every generic drug company's case in a Paragraph IV obviousness challenge under the Hatch-Waxman Act.[1] This is odd because the generic defendant in its validity challenge cannot use anything that the inventors did in support of its obviousness case; but, ironically, the patentee/innovator company can.[2] Given the success rate of Paragraph IV obviousness challenges and the legal framework for the obviousness analysis, one can only wonder why this costly practice continues....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!